{"preliminary_commentary":{"by_channel":{"podcast":8,"youtube":5,"x_thread":1,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04595565\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"SASCIA","nct_id":"NCT04595565","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sascia-nct04595565. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SASCIA","arms":[{"description":"Sacituzumab govitecan is administered intravenously 10 mg/kg body weight on days 1, 8 q3w for eight cycles.","label":"Sacituzumab govitecan","type":"EXPERIMENTAL"},{"description":"TPC, defined as capecitabine or platinum-based chemotherapy for eight cycles or Observation.","label":"Treatment of physician´s choice","type":"OTHER"}],"collaborators":["Gilead Sciences","Austrian Breast & Colorectal Cancer Study Group","Spanish Breast Cancer Research Group (GEICAM)","ETOP IBCSG Partners Foundation","Cancer Trials Ireland","UNICANCER"],"completion_date":{"date":"2029-03-30","type":"ESTIMATED"},"conditions":["HER2-negative Breast Cancer","Triple Negative Breast Cancer"],"enrollment":{"count":1332,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Capecitabine","otherNames":["Xeloda"],"type":"DRUG"},{"name":"Carboplatin","otherNames":["Paraplatin"],"type":"DRUG"},{"name":"Cisplatin","otherNames":["Platinol"],"type":"DRUG"},{"name":"Sacituzumab govitecan","otherNames":["Trodelvy"],"type":"DRUG"}],"last_update":"2026-04-22","lead_sponsor":"GBG Forschungs GmbH","official_title":"Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Primary HER2-negative Breast Cancer Patients With High Relapse Risk After Standard Neoadjuvant Treatment - SASCIA","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-03-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Invasive disease free survival (iDFS) between patients treated with sacituzumab govitecan vs. treatment of physician's choice.","timeFrame":"Assuming 3.25 years of recruitment with 12 months ramp-up and 42 patients per month at peak and 3 years of follow-up after the last patient in, 396 events will be needed and final analysis is expected 75 months after study start."}],"references":[{"citation":"Marmé F, Hanusch C, Furlanetto J, et al. Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment. ESMO Breast 2022; 58O, proffered paper presentation. https://doi.org/10.1016/j.annonc.2022.03.075","pmid":null,"type":"RESULT"}],"start_date":{"date":"2020-10-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sacituzumab Govitecan in Primary HER2-negative Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04595565"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sascia-nct04595565"}